Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s stock price gapped down before the market opened on Monday . The stock had previously closed at $38.24, but opened at $37.05. Ascentage Pharma Group International shares last traded at $36.31, with a volume of 8,478 shares traded.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. began coverage on shares of Ascentage Pharma Group International in a research note on Thursday, March 27th. They issued an "overweight" rating on the stock.
Get Our Latest Stock Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Performance
The stock has a 50 day simple moving average of $31.22. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 3.24.
Hedge Funds Weigh In On Ascentage Pharma Group International
An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC purchased a new stake in shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned about 0.18% of Ascentage Pharma Group International as of its most recent SEC filing.
Ascentage Pharma Group International Company Profile
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
